PluroGen Therapeutics, Inc.
503 Broadleaf Way
Charlottesville, VA 22911
Tel: 443 994 0101
Fax: 410 990 9817
www.plurogen.com
503 Broadleaf Way
Charlottesville, VA 22911
Tel: 443 994 0101
Fax: 410 990 9817
www.plurogen.com
|
FOR IMMEDIATE RELEASE Contact: Adam, J. Katz, M.D.
Secretary, Treasurer
15 March 2006 Board of Directors
Tel:+1 443 994 0101
Fax: +1 410 990 9817
e-Mail:ajkuva@gmail.com
(Charlottesville, VA) – On behalf of the PluroGen™ Therapeutics, Inc., Board of Directors, Chairman George T.
Rodeheaver, PhD has announced that Neal G. Koller has been appointed President & Chief Executive Officer
and has been elected to the Board of Directors of PluroGen™ effective March 15, 2006.
In making the announcement, Rodeheaver stated, “I am extremely pleased that Neal Koller has accepted the
President & Chief Executive Officer position at PluroGen™. His track record as a highly successful global leader
in life sciences will insure that PluroGen™ meets its milestones and grows into the company envisioned by
the Board of Directors and our investors.” “I am honored and excited to have been selected to lead this
globally recognized team at PluroGen™ as President and CEO and look forward to building a strong company
by maximizing the potential of the Company’s very special technology platform to provide a continuous flow of
innovative therapies which improve patient care and outcome,” said Koller.
Mr. Koller comes to PluroGen™ with more than 20 years of experience in medical devices and
bio/pharmaceuticals. Most recently he was President of PDA. Prior to PDA Koller was a founder and
President of WelCare Group, Rome, Italy. Before WelCare, he was President and CEO of Dovetail
Technologies, Inc. CEO of Sound Diagnostics, Inc. and had a long, diverse and very successful affiliation at
the senior managerial level with Sherwood – Davis & Geck, subsidiary of Wyeth Pharmaceuticals. Koller holds
a B.S. in Biology from the University of Richmond.
PluroGenTM Therapeutics, Inc. commercializes novel, superior and patented topical therapeutic products for
improved patient outcomes in management and repair of injured tissues. The Company’s products are based
on our patented, advanced topical drug delivery and drug efficacy enhancement technology platform which
has already been successfully used on over 2,000 patients in the proven, controlled academic environment of
the University of Virginia Health System.
PluroGen™ Therapeutics Vision …
… is to be the premier developer and supplier of comprehensive therapeutic products for the optimum
management and repair of injured tissue.
PluroGen™ Therapeutics Mission …
… is to create novel, simple and advanced products to improve healing of complex wounds to benefit
patients and provide caregivers with new cost-effective wound care options
Secretary, Treasurer
15 March 2006 Board of Directors
Tel:+1 443 994 0101
Fax: +1 410 990 9817
e-Mail:ajkuva@gmail.com
- NEAL G. KOLLER NAMED PLUROGEN™
PRESIDENT AND CHIEF EXECUTIVE OFFICER
(Charlottesville, VA) – On behalf of the PluroGen™ Therapeutics, Inc., Board of Directors, Chairman George T.
Rodeheaver, PhD has announced that Neal G. Koller has been appointed President & Chief Executive Officer
and has been elected to the Board of Directors of PluroGen™ effective March 15, 2006.
In making the announcement, Rodeheaver stated, “I am extremely pleased that Neal Koller has accepted the
President & Chief Executive Officer position at PluroGen™. His track record as a highly successful global leader
in life sciences will insure that PluroGen™ meets its milestones and grows into the company envisioned by
the Board of Directors and our investors.” “I am honored and excited to have been selected to lead this
globally recognized team at PluroGen™ as President and CEO and look forward to building a strong company
by maximizing the potential of the Company’s very special technology platform to provide a continuous flow of
innovative therapies which improve patient care and outcome,” said Koller.
Mr. Koller comes to PluroGen™ with more than 20 years of experience in medical devices and
bio/pharmaceuticals. Most recently he was President of PDA. Prior to PDA Koller was a founder and
President of WelCare Group, Rome, Italy. Before WelCare, he was President and CEO of Dovetail
Technologies, Inc. CEO of Sound Diagnostics, Inc. and had a long, diverse and very successful affiliation at
the senior managerial level with Sherwood – Davis & Geck, subsidiary of Wyeth Pharmaceuticals. Koller holds
a B.S. in Biology from the University of Richmond.
PluroGenTM Therapeutics, Inc. commercializes novel, superior and patented topical therapeutic products for
improved patient outcomes in management and repair of injured tissues. The Company’s products are based
on our patented, advanced topical drug delivery and drug efficacy enhancement technology platform which
has already been successfully used on over 2,000 patients in the proven, controlled academic environment of
the University of Virginia Health System.
PluroGen™ Therapeutics Vision …
… is to be the premier developer and supplier of comprehensive therapeutic products for the optimum
management and repair of injured tissue.
PluroGen™ Therapeutics Mission …
… is to create novel, simple and advanced products to improve healing of complex wounds to benefit
patients and provide caregivers with new cost-effective wound care options
